Alnylam Pharmaceuticals
ALNY
#378
Rank
HK$471.15 B
Marketcap
HK$3,566
Share price
-1.55%
Change (1 day)
78.88%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): HK$1.01 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$3.21 Billion. In 2024 the company made an earning of -HK$1.84 Billion, an increase over its 2023 earnings that were of -HK$2.44 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) HK$1.01 B-155.49%
2024 -HK$1.84 Billion-24.59%
2023 -HK$2.44 Billion-67.84%
2022 -HK$7.56 Billion36.93%
2021 -HK$5.53 Billion-8.04%
2020 -HK$6.01 Billion-15.66%
2019 -HK$7.12 Billion12.23%
2018 -HK$6.35 Billion62.91%
2017 -HK$3.9 Billion17.78%
2016 -HK$3.31 Billion43.44%
2015 -HK$2.31 Billion60.69%
2014 -HK$1.44 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.43 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.34 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-HK$0.59 Billion-157.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
HK$40.05 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$1.97 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$1.25 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$0.37 Billion-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$127.81 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$70.84 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
HK$13.79 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel